Bazedoxifene

Product Description

Bazedoxifene is an indole derivative and third-generation selective estrogen receptor modulator (SERM) with potential antineoplastic activity. Upon administration, bazedoxifene specifically binds to estrogen receptors in responsive tissues, including liver, bone, breast, and endometrium. The resulting ligand-receptor complex is translocated to the nucleus where, depending on the tissue type, it either promotes or suppresses the transcription of estrogen-regulated genes. Bazedoxifene acts as an estrogen antagonist in uterine and breast tissue, thereby blocking the proliferative effects of estrogen-binding to ER-positive cells in these tissues. (Sourced from: https://pubchem.ncbi.nlm.nih.gov/compound/Bazedoxifene)

Mechanisms of Action: ER Modulator

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Oral

FDA Designation: None *

Approval Status: Approved

Approved Countries: Australia | Austria | Bangladesh | Belgium | Brazil | Canada | Chile | Croatia | Cyprus | Czech | Denmark | Estonia | European Medicines Agency | Finland | Greece | Hungary | Iceland | Ireland | Israel | Italy | Japan | Korea | Latvia | Lithuania | Mexico | New Zealand | Norway | Poland | Portugal | Serbia | Slovakia | Slovenia | Spain | Sweden | Switzerland | Taiwan | Thailand | Ukraine | United Kingdom | United States

Approved Indications: Osteoporosis | Osteoporosis, Postmenopausal | Menopause

Known Adverse Events: Abdominal Pain | Dizziness | Neck Pain | Pain Unspecified | Spasm | Diarrhea | Dyspepsia

Company: Pfizer
Company Location: NEW YORK NY 10017
Company CEO: Albert Bourla
Additonal Commercial Interests: None